Overview

This trial is active, not recruiting.

Condition opioid-related disorders
Treatment av411
Phase phase 2
Sponsor New York State Psychiatric Institute
Collaborator National Institute on Drug Abuse (NIDA)
Start date October 2008
End date April 2010
Trial size 30 participants
Trial identifier NCT00723177, #5725, P50 DA009236, P50DA009236

Summary

Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration. The present study is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal symptoms.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose basic science
Arm
(Placebo Comparator)
This group will receive placebo AV411
av411 ibudilast
Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks
(Experimental)
This group will receive a low dose of AV411
av411 ibudilast
Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks
(Experimental)
This group will receive a high dose of AV411
av411 ibudilast
Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks

Primary Outcomes

Measure
Total Subjective Opioid Withdrawal Scale score
time frame: Twice daily for the duration of the trial

Secondary Outcomes

Measure
Pupil diameter, heart rate, blood pressure, respiratory rate, body temperature, other subjective measures, plasma levels of AV411
time frame: Various time points throughout trial

Eligibility Criteria

Male or female participants from 21 years up to 45 years old.

Inclusion Criteria: - Adults between the ages of 21 and 45 - Current dependence on heroin according to DSM-IV criteria - Non-treatment seeking Exclusion Criteria: - Female participants who are currently pregnant or breastfeeding. Lack of effective birth control 10 days before Study Day 1 (15 days prior to the first PET scan) - Self-reported use of methadone, buprenorphine, or levo-alpha-acetylmethadol (LAAM) in the past 14 days - Participants who have a positive history of neurological illness (including epilepsy) or those who have received anti-convulsant therapy during the past 5 years - Liver disease requiring medication or medical treatment, and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit of normal - Gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medication or medical treatment - Neurological or psychiatric disorders including psychosis, bipolar disorder, organic brain disease, any seizure history or other disorders that require treatment or that could make study compliance difficult - Positive tuberculosis (PPD) TB skin test along with a clinical history and chest X-ray indicative of active tuberculosis. (Individuals who have a positive PPD test and have a negative chest X-ray, are not symptomatic for tuberculosis, and do not require anti-tuberculosis therapy will be eligible to participate. Participants will be asked if they ever tested positive for tuberculosis. If so, they will not be given a PPD and a chest X-ray and clinical history will be used for evaluation purposes). - Presence or positive history of severe medical illness or any cardiovascular disease or heart abnormality, such as low hemoglobin (Hb < 13 g/dL in males, Hb < 11 g/dL in females), or BP > 150/90. - Requirement for any of the following medications (current or within the past 4 weeks): psychotropics (including sedative/hypnotics, antidepressants, neuroleptics), anticonvulsants, antihypertensives, antiarrhythmics, or antiretroviral medications,. Participants on any current psychoactive prescription medications will be excluded. - Current dependence (by DSM-IV criteria) on methadone, LAAM, or buprenorphine - Participants for whom detoxification is not "clinically recommended" such as those with a significant history of overdose following detoxification - Participation in an investigational drug study within the past 3 months - Hypersensitivity to any of the medications used in this study - Participants who are positive for HIV or chronic active hepatitis - Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologists: "Guide to MR procedures and metallic objects" Shellock, PhD, Lippincott Williams and Wilkins, NY 2001 - Lifetime exposure to radiation in the workplace, or participation in nuclear medicine procedures, including research protocols, in the past year - Positive Allen Test indicating lack of collateral blood flow to hand - History of Reynaud's syndrome

Additional Information

Official title The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal
Principal investigator Sandra D Comer, PhD
Description Opioid-induced cytokine release and glial activation has been proposed to directly contribute to the affective and physiological aspects of withdrawal. Furthermore, cytokine release following opioid administration has been hypothesized to be a limiting factor in both the duration and magnitude of opioid-induced analgesia. The two primary goals of our study are to assess AV411's ability to 1) reduce the opioid-withdrawal syndrome and 2) increase and prolong the analgesic effects of the mu-opioid agonist, oxycodone. To explore whether AV411 decreases opioid-induced glial cell activation, some participants assigned to the placebo and high dose AV411 groups (n = 6 for each dose condition) will be studied twice with [11C]PK11195, a positron emission tomography (PET) radiotracer used to measure the peripheral benzodiazepine receptor (PBR) in the human brain. The PBR is a receptor located on the mitochondria of the microglia and can be used to examine microglial activation in various brain regions.
Trial information was received from ClinicalTrials.gov and was last updated in December 2012.
Information provided to ClinicalTrials.gov by New York State Psychiatric Institute.